Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Instituto de investigación
Complexo Hospitalario Universitario da Coruña
La Coruña, EspañaPublicaciones en colaboración con investigadores/as de Complexo Hospitalario Universitario da Coruña (13)
2024
-
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial
The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385
2023
-
Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis
The Lancet Regional Health - Europe, Vol. 34
2021
-
European Surveillance System on Contact Allergies (ESSCA): Characteristics of patients patch tested and diagnosed with irritant contact dermatitis
Contact Dermatitis, Vol. 85, Núm. 2, pp. 186-197
2020
-
Holistic approach of the care of the infant with hypoxic-ischaemic encephalopathy in Spain
Anales de Pediatria, Vol. 92, Núm. 5, pp. 286-296
2018
-
Care of the newborn with perinatal asphyxia candidate for therapeutic hypothermia during the first six hours of life in Spain
Anales de Pediatria, Vol. 89, Núm. 4, pp. 211-221
2014
-
HIV-2 and HTLV-1 infections in Spain, a non-endemic region
AIDS Reviews, Vol. 16, Núm. 3, pp. 152-159
2012
-
The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?
Clinical Microbiology and Infection, Vol. 18, Núm. 7
2011
-
Epidemiology of contact dermatitis in Spain. Results of the Spanish surveillance system on contact allergies for the year 2008
Actas Dermo-Sifiliograficas, Vol. 102, Núm. 2, pp. 98-105
-
Impact of obesity in patients infected with 2009 influenza A(H1N1)
Chest, Vol. 139, Núm. 2, pp. 382-386
2008
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
2007
2006
-
Efficacy of lanreotide Autogel® administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial
Clinical Endocrinology, Vol. 65, Núm. 3, pp. 320-326
2003
-
Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer
International Journal of Cancer, Vol. 107, Núm. 5, pp. 781-790